Final APPRAISE-al: Trial Report Argues Against Anticoagulant/Antiplatelet Combos In ACS
This article was originally published in The Pink Sheet Daily
Executive SummaryNEJM article points to much higher bleeding with no compensatory efficacy in failed APPRAISE-2 add-on trial with apixaban.
You may also be interested in...
While the focus of the Cardiovascular and Renal Drugs Advisory Committee’s meeting was on rivaroxaban’s use in treating acute coronary syndromes, some panelists questioned the wisdom of adding an antithrombin to current dual-antiplatelet therapy standard of care. The lack of data on rivaroxaban’s use with the two newest antiplatelet agents, prasugrel and ticagrelor, also could prove problematic from a labeling perspective due to theoretical concerns about increased bleeding.